A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
Completed · Phase 4 · NCT07089706
Conditions: COVID-19
At a glance
- Research payments reported, 2025
- $3.1M
- U.S. investigators named
- 5
- Sites paid
- 6
- Planned or actual enrollment
- 832
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1283.251 Variant-containing Formulation (biological)
- Dates
- Started 2025-07-21; completion 2026-06-16
- Results posted
- Not yet
The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.
From ClinicalTrials.gov, last updated 2026-07-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $3.1M in research payments for this study in 2025 (82 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Robert E. Springer, M.D. Internal Medicine · Atlanta, GA
- Patrick M. Dennis, MD Emergency Medicine · New Orleans, LA
- Taylor W. Sanders, MD Preventive Medicine & Public Health · Prairieville, LA
- Sean C. Kerby, M.D. Family Medicine · Gulfport, MS
- Melita L. Tate, MD Internal Medicine · Tulsa, OK
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Delricht Research $3.1M
- Delricht Clinical Research, LLC $1,058
- Delricht Research Springer $816
- Grassroots Healthcare - Tulsa $748
- Delricht Research - Gulfport $599
- Delricht Research Baton Rouge $599
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.